HOLON, Israel, August 7, 2017 /PRNewswire/ --
Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that CGEN-15032, a newly-disclosed novel myeloid and epithelial immuno-oncology target, will be the subject of both an oral and a poster presentation at the 3rd annual CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference taking place September 6-9, 2017 in Mainz/Frankfurt, Germany.
The presentation titled "Computational discovery and experimental validation of CGEN-15032 as a novel target for cancer immunotherapy" is scheduled as part of the session titled "Other checkpoint blocking and immunomodulating antibodies," on Friday, September 8, 2:00-3:45 pm CEST.
The poster will be presented during the "Checkpoint Blockade Therapy" poster session on Wednesday, September 6, 6:00-8:00 pm CEST (Abstract A146).
CGEN-15032 belongs to a portfolio of novel myeloid and lymphoid target candidates discovered by the Company that are expressed within the tumor microenvironment (TME) of multiple cancers. These targets were discovered using various discovery platforms developed by the Company, including the immune checkpoint discovery platform and immuno-modulatory protein discovery platforms. A number of these targets have demonstrated in vitro checkpoint activity, and a knockout mouse strain for one of them demonstrated reduced tumor growth inhibition in vivo relative to wild type mice. Furthermore, the reduced tumor growth was observed in both the knockout mice alone and when the mice were treated with an anti-PD-L1 inhibitor. Drug candidates against these targets could have the potential to treat both PD-1 responsive and non-responsive patients.
Additional information, not previously disclosed, about the Company's new myeloid and lymphoid targets can be found in an updated corporate presentation (slides 22-24; 44-48) posted on Compugen's website at http://www.cgen.com.
Following the presentation, the poster will be available on Compugen's website.
About Compugen
Compugen is a therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered, including T cell immune checkpoints and myeloid target programs. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with R&D facilities in both Israel and South San Francisco, CA. Compugen's shares are listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at http://www.cgen.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," and "intends," and describe opinions about possible future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen's business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model. Moreover, the development and commercialization of therapeutic candidates involve many inherent risks, including failure to progress to clinical trials or, if they progress to or enter clinical trials, failure to receive regulatory approval. These and other factors are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.
Company contact: Elana Holzman Director, Investor Relations and Corporate Communications Compugen Ltd. Email: [email protected] Tel: +972(3)765-8124
SOURCE Compugen Ltd.
Advertisement
Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that CGEN-15032, a newly-disclosed novel myeloid and epithelial immuno-oncology target, will be the subject of both an oral and a poster presentation at the 3rd annual CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference taking place September 6-9, 2017 in Mainz/Frankfurt, Germany.
Advertisement
The presentation titled "Computational discovery and experimental validation of CGEN-15032 as a novel target for cancer immunotherapy" is scheduled as part of the session titled "Other checkpoint blocking and immunomodulating antibodies," on Friday, September 8, 2:00-3:45 pm CEST.
The poster will be presented during the "Checkpoint Blockade Therapy" poster session on Wednesday, September 6, 6:00-8:00 pm CEST (Abstract A146).
CGEN-15032 belongs to a portfolio of novel myeloid and lymphoid target candidates discovered by the Company that are expressed within the tumor microenvironment (TME) of multiple cancers. These targets were discovered using various discovery platforms developed by the Company, including the immune checkpoint discovery platform and immuno-modulatory protein discovery platforms. A number of these targets have demonstrated in vitro checkpoint activity, and a knockout mouse strain for one of them demonstrated reduced tumor growth inhibition in vivo relative to wild type mice. Furthermore, the reduced tumor growth was observed in both the knockout mice alone and when the mice were treated with an anti-PD-L1 inhibitor. Drug candidates against these targets could have the potential to treat both PD-1 responsive and non-responsive patients.
Additional information, not previously disclosed, about the Company's new myeloid and lymphoid targets can be found in an updated corporate presentation (slides 22-24; 44-48) posted on Compugen's website at http://www.cgen.com.
Following the presentation, the poster will be available on Compugen's website.
About Compugen
Compugen is a therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered, including T cell immune checkpoints and myeloid target programs. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with R&D facilities in both Israel and South San Francisco, CA. Compugen's shares are listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at http://www.cgen.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," and "intends," and describe opinions about possible future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen's business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model. Moreover, the development and commercialization of therapeutic candidates involve many inherent risks, including failure to progress to clinical trials or, if they progress to or enter clinical trials, failure to receive regulatory approval. These and other factors are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.
Company contact: Elana Holzman Director, Investor Relations and Corporate Communications Compugen Ltd. Email: [email protected] Tel: +972(3)765-8124
SOURCE Compugen Ltd.
